Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
METAGENOMI THERAPEUTICS INC (MGX) Stock Price & Overview
NASDAQ:MGX • US59102M1045
Current stock price
1.39 USD
+0.01 (+0.72%)
At close:
1.4 USD
+0.01 (+0.72%)
After Hours:
The current stock price of MGX is 1.39 USD. Today MGX is up by 0.72%. In the past month the price increased by 2.96%. In the past year, price decreased by -13.66%.
MGX Key Statistics
52-Week Range1.25 - 3.95
Current MGX stock price positioned within its 52-week range.
1-Month Range1.3095 - 1.55
Current MGX stock price positioned within its 1-month range.
- Market Cap
- 52.292M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.37
- Dividend Yield
- N/A
MGX Stock Performance
Today
+0.72%
1 Week
-7.33%
1 Month
+2.96%
3 Months
-9.74%
Longer-term
6 Months -45.28%
1 Year -13.66%
2 Years -78.21%
3 Years N/A
5 Years N/A
10 Years N/A
MGX Stock Chart
MGX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to MGX. When comparing the yearly performance of all stocks, MGX is a bad performer in the overall market: 81.55% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
MGX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MGX. While MGX has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
MGX Earnings
On March 5, 2026 MGX reported an EPS of -0.6 and a revenue of 3.91M. The company beat EPS expectations (1.87% surprise) and missed revenue expectations (-42.59% surprise).
Next Earnings DateMay 19, 2026
Last Earnings DateMar 5, 2026
PeriodQ4 / 2025
EPS Reported-$0.60
Revenue Reported3.911M
EPS Surprise 1.87%
Revenue Surprise -42.59%
MGX Forecast & Estimates
9 analysts have analysed MGX and the average price target is 9.52 USD. This implies a price increase of 584.89% is expected in the next year compared to the current price of 1.39.
For the next year, analysts expect an EPS growth of 9.76% and a revenue growth -15.35% for MGX
Analysts
Analysts80
Price Target9.52 (584.89%)
EPS Next Y9.76%
Revenue Next Year-15.35%
MGX Index Membership
MGX is currently included in the following stock indexes tracked on ChartMill.
MGX Financial Highlights
Over the last trailing twelve months MGX reported a non-GAAP Earnings per Share(EPS) of -2.37. The EPS increased by 9.54% compared to the year before.
Income Statements
Revenue(TTM)25.21M
Net Income(TTM)-87.87M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.74% | ||
| ROE | -55.4% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%4.76%
Sales Q2Q%-59.32%
EPS 1Y (TTM)9.54%
Revenue 1Y (TTM)-51.79%
MGX Ownership
Ownership
Inst Owners20.14%
Shares37.62M
Float27.06M
Ins Owners8.92%
Short Float %6.91%
Short Ratio8.54
MGX Industry Overview
MGX operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
MGX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MGX
Company Profile
Metagenomi Therapeutics, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. The company is headquartered in Emeryville, California and currently employs 119 full-time employees. The company went IPO on 2024-02-09. The company is developed to discover and develop a suite of novel editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. The company focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. MGX-001, its lead, wholly owned development program in hemophilia A, has demonstrated a preclinical profile potentially competitive with treatment options, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A. MGX-001 is designed to insert a Factor VIII (FVIII) DNA cassette into a safe harbor location within an intron of the albumin gene.
Company Info
IPO: 2024-02-09
METAGENOMI THERAPEUTICS INC
5959 Horton St, Floor 7
Emeryville CALIFORNIA US
Employees: 119
Phone: 15108714880
METAGENOMI THERAPEUTICS INC / MGX FAQ
Can you describe the business of METAGENOMI THERAPEUTICS INC?
Metagenomi Therapeutics, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. The company is headquartered in Emeryville, California and currently employs 119 full-time employees. The company went IPO on 2024-02-09. The company is developed to discover and develop a suite of novel editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. The company focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. MGX-001, its lead, wholly owned development program in hemophilia A, has demonstrated a preclinical profile potentially competitive with treatment options, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A. MGX-001 is designed to insert a Factor VIII (FVIII) DNA cassette into a safe harbor location within an intron of the albumin gene.
What is the current price of MGX stock?
The current stock price of MGX is 1.39 USD. The price increased by 0.72% in the last trading session.
Does METAGENOMI THERAPEUTICS INC pay dividends?
MGX does not pay a dividend.
What is the ChartMill technical and fundamental rating of MGX stock?
MGX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for MGX stock?
METAGENOMI THERAPEUTICS INC (MGX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.37).
Is METAGENOMI THERAPEUTICS INC (MGX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MGX.
What is the Short Interest ratio of METAGENOMI THERAPEUTICS INC (MGX) stock?
The outstanding short interest for METAGENOMI THERAPEUTICS INC (MGX) is 6.91% of its float.